Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies.
anti-programmed death-1 (PD-1)
biomarkers
immune checkpoint inhibitors
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
16 Dec 2021
16 Dec 2021
Historique:
received:
30
10
2021
revised:
09
12
2021
accepted:
14
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to predict the therapeutic effect of ICIs. Therefore, this study investigated the clinical implications of plasma levels of soluble anti-programmed death-1 (sPD-1) in patients with cancer treated with ICIs. In total, 22 patients (13 with non-small-cell lung carcinoma, 8 with gastric cancer, and 1 with bladder cancer) were evaluated for sPD-1 concentration using enzyme-linked immunosorbent assays for diagnostic and anti-PD-1 antibody analyses. sPD-1 levels were low before the administration of anti-PD-1 antibodies. After two and four cycles of anti-PD-1 antibody therapy, sPD-1 levels significantly increased compared with pretreatment levels (
Identifiants
pubmed: 34944745
pii: biomedicines9121929
doi: 10.3390/biomedicines9121929
pmc: PMC8698555
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Medicine (Baltimore). 2017 May;96(18):e6369
pubmed: 28471952
Anticancer Res. 2019 Sep;39(9):5195-5201
pubmed: 31519633
Scand J Immunol. 2017 Nov;86(5):361-367
pubmed: 28930374
Oncoimmunology. 2017 Mar 31;6(5):e1310358
pubmed: 28638732
Scand J Rheumatol. 2014;43(2):101-8
pubmed: 24182347
Cancers (Basel). 2020 Nov 16;12(11):
pubmed: 33207823
Cell Immunol. 2005 Jun;235(2):109-16
pubmed: 16171790
Lung Cancer. 2016 Oct;100:77-84
pubmed: 27597284
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Oncotarget. 2019 Sep 03;10(51):5359-5371
pubmed: 31523394
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Manag Res. 2020 Oct 07;12:9691-9709
pubmed: 33116828
Clin Breast Cancer. 2019 Oct;19(5):326-332.e1
pubmed: 31176611
Oncoimmunology. 2019 Feb 3;8(4):e1561120
pubmed: 30906655
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
Oncoimmunology. 2020 Nov 25;9(1):1846901
pubmed: 33299657
Immunity. 2004 Mar;20(3):337-47
pubmed: 15030777
PLoS One. 2019 Feb 26;14(2):e0212978
pubmed: 30807610
Cancer Immunol Immunother. 2019 Mar;68(3):353-363
pubmed: 30506460
Int J Clin Oncol. 2016 Jun;21(3):462-73
pubmed: 26899259
Asian Pac J Cancer Prev. 2012;13(8):4031-6
pubmed: 23098512
Cancer Immunol Immunother. 2021 Feb;70(2):337-348
pubmed: 32757055
J Immunother. 2011 Apr;34(3):297-306
pubmed: 21389868
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Oncoimmunology. 2020 Jun 16;9(1):1774314
pubmed: 32923134
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
J Immunother Cancer. 2020 May;8(1):
pubmed: 32457125
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Immunother Cancer. 2018 Nov 27;6(1):132
pubmed: 30482248
Int J Biol Markers. 2015 Nov 11;30(4):e364-8
pubmed: 26349666
Crit Rev Oncol Hematol. 2019 Nov;143:148-152
pubmed: 31675543
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
J Immunother. 2020 Jun;43(5):156-164
pubmed: 32168233